INDOCOBSEIndoco Remedies LtdMediumPositive
Announced Thu, 14 May · 11:02 IST

Press Release:- Indoco Remedies successfully clears Malta Medicines Authority Audit

Regulatory Product ApprovalBusiness Updates View source PDF

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.4%1-day move
₹226.00
prior close
₹225.81
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.3+0.2+0.8+0.5-0.4-4.9-5.5-6.8-9.4-13.4-8.0+6.1+9.9
Up moveDown movePending
AI summary

Indoco Remedies' manufacturing facility for solid oral dosage form at Baddi (Unit I) has successfully cleared an audit by the Malta Medicines Authority conducted from January 29 to February 3, 2026. The facility has received EU GMP certification, confirming compliance with European Good Manufacturing Practice requirements as per the EC Directive. This certification validates the company's quality standards and regulatory compliance for the European market. The company is a fully integrated pharmaceutical firm with US$ 175 million turnover, 10 manufacturing facilities, and approvals from major regulatory bodies including USFDA and UK-MHRA.

Likely market impact

This regulatory approval enhances Indoco's credibility for exporting to European markets, potentially supporting future revenue growth in hard currency markets. It validates the company's quality standards and strengthens its global regulatory standing.